Organogenesis (NASDAQ:ORGO) Trading 10.8% Higher – Time to Buy?

Organogenesis Holdings Inc. (NASDAQ:ORGO) shot up 10.8% on Friday . The stock traded as high as $4.10 and last traded at $4.15. 632,813 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 1,095,408 shares. The stock had previously closed at $3.75.

Analyst Ratings Changes

Separately, Morgan Stanley increased their target price on Organogenesis from $4.00 to $6.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 5th.

Organogenesis Stock Performance

The stock’s fifty day moving average price is $4.31 and its two-hundred day moving average price is $3.67. The company has a market cap of $540.29 million, a P/E ratio of -71.00 and a beta of 1.79. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09.

Insider Activity at Organogenesis

In other news, Director Michael Joseph Driscoll sold 25,000 shares of Organogenesis stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total transaction of $127,500.00. Following the sale, the director now directly owns 166,879 shares of the company’s stock, valued at approximately $851,082.90. This trade represents a 13.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 36.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. boosted its position in Organogenesis by 54.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock valued at $9,443,000 after acquiring an additional 1,035,120 shares during the last quarter. Soleus Capital Management L.P. lifted its stake in shares of Organogenesis by 5.4% in the 4th quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company’s stock valued at $39,952,000 after purchasing an additional 645,000 shares during the period. Norges Bank bought a new stake in shares of Organogenesis during the 4th quarter valued at about $1,543,000. Dimensional Fund Advisors LP grew its stake in Organogenesis by 18.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company’s stock worth $8,925,000 after purchasing an additional 442,772 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in Organogenesis by 31.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,073,500 shares of the company’s stock worth $3,435,000 after purchasing an additional 255,600 shares in the last quarter. 49.57% of the stock is owned by institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.